Cargando…
Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD
The present study was aimed at assessing the capability of Aβ1-40 and Aβ1-42 levels in undiluted plasma (UP), diluted plasma (DP), and cell bound (CB) to distinguish between early stages of Alzheimer's disease (AD), amnesic mild cognitive impairment (MCI), and healthy control (HC). Four blood s...
Autores principales: | Pesini, Pedro, Pérez-Grijalba, Virginia, Monleón, Inmaculada, Boada, Mercè, Tárraga, Lluís, Martínez-Lage, Pablo, San-José, Itziar, Sarasa, Manuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431090/ https://www.ncbi.nlm.nih.gov/pubmed/22957297 http://dx.doi.org/10.1155/2012/604141 |
Ejemplares similares
-
Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study
por: Pérez-Grijalba, Virginia, et al.
Publicado: (2019) -
Blood Amyloid Beta Levels in Healthy, Mild Cognitive Impairment and Alzheimer’s Disease Individuals: Replication of Diastolic Blood Pressure Correlations and Analysis of Critical Covariates
por: Ruiz, Agustín, et al.
Publicado: (2013) -
Correction: Blood Amyloid Beta Levels in Healthy, Mild Cognitive Impairment and Alzheimer’s Disease Individuals: Replication of Diastolic Blood Pressure Correlations and Analysis of Critical Covariates
por: Ruiz, Agustín, et al.
Publicado: (2014) -
Association between cell-bound blood amyloid-β(1–40) levels and hippocampus volume
por: Sotolongo-Grau, Oscar, et al.
Publicado: (2014) -
Safety, tolerability and immunogenicity of an active anti-Aβ(40) vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial
por: Lacosta, Ana-María, et al.
Publicado: (2018)